Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > IMVT Immunovant > Key Indicators
IMVT Immunovant
9.340
+1.170+14.32%
Pre Mkt Price
9.3400.0000.00%
YOY
Do not show
Hide blank lines
(Q1)2022/06/30(FY)2022/03/31(Q4)2022/03/31(Q3)2021/12/31
Financial Ratios
Efficiency Ratios TTM
ROIC
-18.9% -41.288% 17.16% -36.151% 17.16% -36.151% 20.55% -29.759%
ROE
-18.33% -41.553% 17.76% -36.394% 17.76% -36.394% 21.06% -29.961%
ROA
-20.06% -39.361% 17.96% -33.776% 17.96% -33.776% 20.91% -28.215%
Efficiency Ratios
Profitability Ratios TTM
Financial Health Ratios
Long-Term Debt to Equity Ratio
-60.98% 0.211% -54.61% 0.260% -54.61% 0.260% -42.42% 0.333%
Total Assets to Common Equity
-1.01% 105.078% 4.15% 109.735% 4.15% 109.735% 2.84% 107.529%
Debt to Asset Ratio
-42.92% 0.477% -42.35% 0.503% -42.35% 0.503% -35.29% 0.546%
Current Ratio
14.55% 21.4792 -47.12% 11.5214 -47.12% 11.5214 -42.93% 14.8671
Quick Ratio
12.25% 20.7297 -46.68% 11.3809 -46.68% 11.3809 -43.43% 14.4964
GrowthRatios
Growth Ratios
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Immunovant, Inc. is a clinical-stage biopharmaceutical company. The firm focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.
CEO: Dr. Peter Salzmann, M.B.A.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...